

CBNB (Chemical Business NewsBase)

Subject Coverage	News affecting the chemical industry: <ul style="list-style-type: none"> • Company information • Products and production • Market information • Environmental aspects • Legal aspects and regulations 			
File Type	Bibliographic			
Features	Thesaurus	None		
	Alerts (SDIs)	Weekly		
	CAS Registry Number® Identifiers	<input checked="" type="checkbox"/>	SLART	<input checked="" type="checkbox"/>
	Keep & Share	<input checked="" type="checkbox"/>	Structures	<input type="checkbox"/>
Record Content	<ul style="list-style-type: none"> • Records contain bibliographic information, controlled indexing for company and country names, chemical names and important concepts, CAS Registry Numbers®, and an abstract. 			
File Size	<ul style="list-style-type: none"> • More than 2.0 million records (08/2022) 			
Coverage	1984-present			
Updates	Daily			
Language	English			
Database Producer	Elsevier Engineering Information Inc. 1 Castle Point Terrace Hoboken, New Jersey 07030-5996 USA Phone: +1 201 216-8500 Fax: +1 201 216-8532 Email: eicustomersupport@elsevier.com Copyright Holder			

Sources

- Newspapers
 - Journals
 - Company reports
 - Stockbroker reports
 - Market research reports
 - Books
 - Press releases
 - Trade literature
 - Advertisements
 - Government and EU publications
 - Directories
-

User Aids

- Online Helps (HELP DIRECTORY lists all help messages available)
 - STNGUIDE
-

Cluster

- AGRICULTURE
- ALLBIB
- BUSINESS
- CASRNS
- CHEMENG
- CHEMISTRY
- COMPANIES
- ENVIRONMENT
- FUELS
- GOVREGS
- HEALTH
- MATERIALS
- PETROLEUM
- PHARMACOLOGY
- POLYMERS

STN Database Cluster information:

<http://www.stn-international.com/en/customersupport/customer-support#cluster+%7C+subjects+%7C+features>

Search and Display Field Codes

Fields that allow left truncation are indicated by an asterisk (*).

General Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index* (contains single words from the title (TI)*, abstract (AB)*, classification code (CC), corporate name (CO), geographical term (GT), controlled term (CT), and chemical name (CN) fields, as well as CAS Registry Numbers)	None or (/BI)	S ICI AND KLEA S SPECIALITY CHEMICAL# AND SOUTH AFRICA S 50-78-2 S ?TRIAZOL?	TI, AB, CC, CO, GT, CT, CN, RN
Accession Number	/AN	S 3545040781/AN S 0544032094/AN	AN
Abstract*	/AB	S CONSUMER DEMAND/AB	AB
Classification Code (1)	/CC	S MS-19/CC S SPECIALITY CHEMICALS/CC	CC
Chemical Name*	/CN	S ASPIRIN/CN S DIETHYLENE GLYCOL/CN	CN
Corporate Name (1)	/CO	S ICI AUSTRALIA/CO	CO
Controlled Term	/CT	S PLANT CAPACITY/CT	CT
Controlled Word	/CW	S PLANT CAPACITY/CW	CT
Document Number	/DN	S TCD3545040761	DN
Document Type (code and text)	/DT	S JOURNAL/DT	DT
Entry Date (2)	(or /TC) /ED (or /UP)	S J/DT S ED>JAN 2008	ED
Geographic Term (code and text)	/GT	S NORTH AMERICA/GT S 21/GT	GT
International Standard (Document) Number (CODEN, ISBN, and ISSN)	/ISN	S 1-85056-091-9/ISN S EKEPAB/ISN S 0014-0058/ISN	ISN, SO
Journal Title	/JT	S CHEMICAL MARKETING REPORTER/JT	JT, SO
Language (ISO code and text)	/LA	S GERMAN/LA S DE/LA	LA
Publication Date (2)	/PD	S NOV 1989/PD	PD, SO
Publication Year (2)	/PY	S 1999-2000/PY	PY, PD, SO
Reference	/RE	S POLIS-954990605/RE	RE
CAS Registry Number	/RN	S 550-78-2/RN	RN
Standard Industrial (Classification) Code (code and text) (1)	/SIC	S 2853/SIC S 285/SIC S 28/SIC S COATINGS/SIC	SIC
Source (contains journal title and other higher level titles, ISBN, ISSN, CODEN, publishing information)	/SO	S CHEMICAL WEEK/SO AND DEC 1989/SO S HOECHST ANNUAL REPORT/SO	SO
Title*	/TI	S CFC REPLACEMENT#/TI	TI

(1) Searching with implied (S) proximity is available in this field.

(2) Numeric search field that may be searched using numeric operators or ranges.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI CO. The fields are displayed or printed in the order requested.

Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC, and OCC formats.

Format	Content	Examples
AB AN CC CN CO CT DN DT (TC) GT ISN (1) JT (1) LA PD (1) PY (1) RE RN SIC SO TI	Abstract Accession Number Classification Code Chemical Name Corporate Name Controlled Term Document Number Document Type Geographic Term International Standard (Document) Number Journal Title Language Publication Date Publication Year Reference CAS Registry Number Standard Industrial (Classification) Code Source Title	D TI AB D 1-5 AN D CC CT D CN D CO D CT CC D DN D DT LA D GT D ISN D JT D LA D PD D PY D RE D RN 1-3 D SIC D L5 SO D TI 1-10
ABS ALL IALL BIB IBIB IND SCAN (2) TRIAL (TRI, SAMPLE, SAM, FREE)	AN, AB, RE BIB, AB, RE, CC, GT, CT, CN, RN, SIC, CO ALL, indented with text labels AN, TI, SO, DT, LA, AV, ED BIB, indented with text labels AN, DN, CC, GT, CT, CN, RN, SIC, CO TI, CC, GT, CT, RN, CO (random display without answer numbers) AN, TI, CC, GT, CT, RN, CO	D ABS D ALL 1-10 D IALL D BIB D IBIB D L5 IND D SCAN D TRI
HIT KWIC OCC	Hit term(s) and field(s) Up to 50 words before and after hit term(s) (KeyWord-In-Context) Number of occurrences of hit term(s) and field(s) in which they occur	D HIT D KWIC D OCC

(1) Custom display only.

(2) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

SELECT, ANALYZE, and SORT Fields (cont'd)

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y (2)	N
Accession Number	AN	Y	N
Classification Code	CC	Y	Y
Chemical Name	CN	Y	Y
Corporate Name	CO	Y	Y
CODEN	CODEN	N	Y
Controlled Term	CT	Y	N
Document Type	DT (TC)	Y	Y
Geographic Term	GT	Y	Y
International Standard Book Number	ISBN	N	Y
International Standard (Document) Number	ISN	Y (3)	N
International Standard Serial Number	ISSN	N	Y
Journal Title	JT	Y	Y
Publication Date	PD	Y	Y
Publication Year	PY	Y (4)	Y
Reference	RE	Y	N
CAS Registry Number	RN	Y	Y
Standard Industrial (Classification) Code	SIC	Y	Y
Source	SO	Y (5)	N
Title	TI	Y (default)	Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT TI.

(2) Appends /BI to the terms created by SELECT.

(3) Selects or analyzes ISSN, ISBN, and CODEN with /ISN appended to the terms created by SELECT.

(4) SELECT HIT and ANALYZE HIT are not valid with this field.

(5) Selects or analyzes ISSN, ISBN, and CODEN with /SO appended to the terms created by SELECT.

Sample Records**DISPLAY ALL OF JOURNAL**

AN 3545040761 CBNB

DN TCD3545040761

TI Opinion/decision on a Paediatric investigation plan (PIP): Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran), P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0186/2019 (EMA-001855-PIP01-15).

SO EMA (European Medicines Agency) (Oct 2019), 1-10, (900 plus words)

DT Journal; (Overview)

LA English

AV Website: <http://www.ema.europa.eu>

ED Entered STN: 8 Nov 2019

Last updated on STN: 8 Nov 2019

AB On 29 Oct 2019, the European Medicines Agency published decision P/0186/2019 of 15 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran) (EMA-001855-PIP01-15). A paediatric investigation plan for synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines

Agency annexed hereto, together with its appendices, is hereby agreed. A deferral for synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted. A waiver for synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted. This decision is addressed to Genzyme Europe BV, Paasheuvelweg 25, 1105 BP - Amsterdam, The Netherlands. Indication(s): Treatment of congenital haemophilia; and a treatment of congenital haemophilia B. The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee. Original Source: EMA: EMA/256057/2019: European Medicines Agency decision P/0186/2019 of 15 May 2019 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran) (EMEA-001855-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council; https://www.ema.europa.eu/documents/pip-decision/p/0186/2019-ema-decision-15-may-2019-agreement-pip-granting-deferral-waiver-synthetic-double-stranded-sirna_en.pdf; 15 May 2019.

CC MS-04 Pharmaceuticals Prosthetics and Medical Chemistry; LA-40 Permits and Patents; MS-21 Biotechnology
GT 1110 European Union
CT regulations and rulings
CN oligonucleotides; ligands; haemophilia B treatments; haemophilia treatments; fitusiran
SIC 2836 Biological Products; 2899 Chemical Products NEC; 28341 Cardiovascular Preparations
CO Genzyme Europe

DISPLAY ALL OF PRESS RELEASE

AN 2647064544 CBNB
DN TCD2647064544
TI Potash One agrees to friendly takeover by K+S for C\$4.50 per share in cash.
SO (22 Nov 2010), (200-899 words)
DT Press Release; (Column)
LA English
AV K+S AG, Bertha-von-Suttner-Strasse 7, 34131 Kassel, Germany, tel: +49 5619 3010, fax: +49 5619 30117 53, website: www.k-plus-s.com
ED Entered STN: 5 Jan 2016
Last updated on STN: 14 Mar 2017
AB On 22 Nov 2010, K+S AG and Potash One Inc announced that they have entered into a Support Agreement pursuant to which K+S will make an offer to acquire all of the issued and outstanding common shares of Potash One at a price of C\$4.50 per share in cash for total consideration of approximately C\$434 M (EUR 311 M). The offer represents a: 24.3% premium to the closing price of Potash One shares on 19 Nov 2010 on the Toronto Stock Exchange; 31.3% premium over the 10-day weighted average trading price of the shares up to and including 19 Nov

2010; and 82.2% premium to Potash One's share price of CAD 2.47 on 16 Aug 2010, the day prior to Potash Corp's rejection of BHP Billiton's unsolicited proposal. The Potash One Board of Directors has unanimously determined that the transaction is fair to Potash One shareholders and is in the best interests of the company and its shareholders. The Board recommends that shareholders tender their common shares to the offer. Potash One's Board has received an opinion from GMP Securities L.P. that the consideration to be received by the Potash One shareholders under the offer is fair from a financial point of view to those shareholders. Potash One holds several potash exploration licenses in the Canadian province of Saskatchewan, including the Legacy Project, an advanced greenfield project to develop a potash solution mine. K+S estimates production capacity of up to 2.7 M tonnes/y of potassium chloride. The realisation of this production capacity would represent an approximately \$2.5 bn capital investment into Saskatchewan and create up to 300 highly-skilled jobs. The project headquarters will be located in Saskatchewan, Canada. K+S expects initial production no earlier than 2015.

CC MS-06 Fertilizers
GT 1112 Germany; 2103 Canada
CT mergers and acquisitions; investment; plant capacity; employment
CN potassium chloride
RN 7447-40-7
SIC 28194 Potassium and Sodium Compounds
CO Kali und Salz (K+S); Potash One

In North America

CAS Customer Center
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.

Phone: 800-753-4227 (North America)
614-447-3731 (worldwide)
Email: help@cas.org
Internet: www.cas.org

In EMEA

CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

Phone: +49-7247-808-555
E-mail: EMEAhelp@cas.org

In Japan

JAICI (Japan Association for
International Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan

Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
Email: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp